News
-
-
-
COMMUNIQUÉ DE PRESSE
CEO transition at Neovii Pharmaceuticals: Frédéric Prince to succeed Christian Loss, effective January 1st, 2026
Frédéric Prince to succeed Christian Loss as CEO of Neovii Pharmaceuticals on January 1st, 2026. Dr. Loss retires after distinguished career. Dr. Prince brings extensive experience in research & development and commercial functions -
-
-
COMMUNIQUÉ DE PRESSE
DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs)
DiNABIOS celebrates U.S. Senate passage of FDA Modernization Act 3.0, promoting human-relevant NAMs for drug development and reducing animal testing -
-
-
COMMUNIQUÉ DE PRESSE
DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies
DiNAQOR and academic partners introduce groundbreaking percutaneous platform for organ-specific delivery of advanced therapies, addressing critical challenges in gene and cell therapy development -
